We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Amgen Inc | NASDAQ:AMGN | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.82 | 0.27% | 300.30 | 300.31 | 300.98 | 302.91 | 298.51 | 301.75 | 2,451,956 | 22:02:00 |
From May 2019 to May 2024
By Colin Kellaher
Biotechnology startup Nkarta Therapeutics on Wednesday said it raised $114 million in an oversubscribed Series B funding round at an undisclosed valuation.
Nkarta, which is developing engineered natural killer cell therapies to fight cancer, said new investor Samsara BioCapital led the round.
New investors Amgen Inc.'s (AMGN) Amgen Ventures, Deerfield Management, Life Science Partners, Logos Capital and RA Capital Management also participated, joined by existing investors NEA Ventures, SR One and Novo Holdings A/S, Nkarta said.
The South San Francisco, Calif., company, founded in 2015, said it will use the funding to advance multiple programs into clinical trials.
Nkarta, which previously raised $11 million in a Series A financing, also said it expects to complete a manufacturing facility in South San Francisco next year to supply investigational product for its early-stage clinical trials.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
September 04, 2019 12:13 ET (16:13 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
1 Year Amgen Chart |
1 Month Amgen Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
